

Number 731 • April 2018

## Product supply shortage addressed for *Alberta Drug* Benefit List (ADBL)

Alberta Blue Cross has been advised by Sandoz Canada Inc and Teva Canada Limited that the shortages for Sandoz Naratriptan 2.5 mg Tablet (DIN 02322323) and Teva-Naratriptan 2.5 mg Tablet (DIN 02314304) respectively have been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **April 26, 2018**.

## NARATRIPTAN HCL

## 2.5 MG TABLET

00002322323	SANDOZ NARATRIPTAN	SDZ	\$ 6.1436
00002314304	TEVA-NARATRIPTAN	TEV	\$ 6.1436
00002237821	AMERGE	GSK	\$ 15.5017

## When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

**780-498-8370** (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free) **FAX 780-498-8406** (Edmonton and area) • **FAX 1-877-305-9911** (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims. **Visit** ab.bluecross.ca/providers/pharmacy-home.php



\*\*The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. \*† Blue Shield is a registered trade-mark of the Blue Cross Blue Shield Association. ABC 82320.731 2018/04

